



Airfinity May Data Set

Source: [Airfinity](#)



Contact Airfinity: infectiousdiseases@airfinity.com

Contact IFPMA: info@ifpma.org


May 2023

COVID-19 treatment candidate pipeline

- U.S./U.K./E.U. Approved:**
- Remdesivir (Full approval)
 - Baricitinib (Full approval)
 - Tocilizumab (EUA)
 - Sarilumab (EUA)
 - Anakinra (EUA)
 - Dexamethasone (EUA)
 - Hydrocortisone (EUA)
 - LY-CoV555 mono-therapy (EUA)
 - REGEN-COV (EUA)
 - CT-P59 (EUA)
 - Sotrovimab (EUA)
 - Evusheld (EUA)
 - Paxlovid (Nirmatrelvir with Ritonavir) (EUA)
 - LY-CoV1404 (EUA)
 - LY-CoV555 + LY-CoV016 combination (EUA)
 - Molnupiravir (EUA)
 - Ifx-1 (Vilobelimab) (EUA)




■ Repurposed
■ Not Repurposed
■ Unknown



- Tocilizumab, Dexamethasone, Nirmatrelvir+Ritonavir, Baricitinib, Sarilumab, Remdesivir, Molnupiravir

*Repurposed = candidate is **approved** for an alternate disease indication

COVID-19 therapeutics collaboration deals



For total collaborations: 176 signed
 158 for manufacturing and 18 for distribution (176-18 = 158) 165 are active, 148 for manufacturing and 17 for distribution

Of the total manufacturing agreements signed - 158
 148 are active and at least 10 are inactive

Total Collaborations
176

Collaborations include : Distribution and commercialisation partners, Voluntary Licensing Agreements, Manufacturing partners, Medicines Patent Poll sublicensees


Note: interruption of deals is often not announced publicly, therefore the number of inactive deals may differ.

43 manufacturing licensing agreements were signed in the first year of the pandemic, tripling by June 2022

- **44** generic manufacturers signed **MPP** VLAs for **Paxlovid** (Nirmatrelvir; Ritonavir) – **38** parent companies and **6** of their subsidiaries – 3 parent companies have since withdrawn from the MPP bringing the total to **35 MPP sublicensees** with an **additional 6 of subsidiaries**.
- **29** generic manufacturers signed **MPP** VLAs for **Molnupiravir** – **27** parent companies and **2** of their subsidiaries – 4 parent companies have since withdrawn from the MPP bringing the total to **23 MPP sublicensees** with an **additional 2 of subsidiaries**.
- **MSD*** signed bilateral VLAs with **8** generic manufacturers for **Molnupiravir**
- **Eli Lilly** signed bilateral VLAs with **8** generic manufacturers for **Baricitinib**
- **Gilead** signed bilateral VLAs with **9** generic manufacturers for **Remdesivir**

- *Known as Merck in the United States and Canada, and as MSD outside of the United States and Canada.
- Manufacturing agreements are recorded when announced. Agreements can be amended/removed following company updates.

Cumulative Manufacturing Agreements



1 relevant agreement between Regeneron and Sanofi for the production of Sarilumab pre-dates 2020 (2007)


158 manufacturing deals were signed by the end of the **second year** of the pandemic, **10** of which have since been inactive

148 active – 10 inactive
Total 158 signed


(does not include distribution deals)

Note: interruption of deals is often not announced publicly, therefore the number of inactive deals may differ.

43 manufacturing licensing agreements were signed in the first year of the pandemic, tripling by June 2022




Existing voluntary licensing agreements map: location of licensees and sublicensees for Nirmatrelvir + Ritonavir, Molnupiravir and Remdesivir



Overview of WHO recommended COVID-19 therapeutic approvals

Regulatory decisions on the 7 WHO recommended COVID-19 treatments worldwide




WHO Recommended COVID-19 Treatments:

- Remdesivir
- Nirmatrelvir + Ritonavir
- Molnupiravir
- Tocilizumab
- Sarilumab
- Baricitinib
- Dexamethasone

COVID-19 therapeutic collaborations: India

- Finished drug product
- API/excipient
- Distribution/Commercialisation



Total Collaborations*
68

Collaborations include : Distribution partners, VLAs, Manufacturing partners, MPP sublicensees

Source: 2023 Airfinity (Last Updated: March 2023)